⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29192982 | 1.00 | — | — | |
| SCHEMBL14737710 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL20659484 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL29821508 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL20659482 | 0.94 | — | — | |
| SCHEMBL1230754 | 0.81 | — | — | |
| SCHEMBL12818092 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL25305032 | 0.76 | — | — | |
| SCHEMBL21447691 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL25353451 | 0.75 | IDH1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250388560-A1 | AROMATIC COMPOUND AND USE THEREOF | HITGEN INC (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4653421-A1 | AROMATIC-RING COMPOUND AND USE THEREOF | Hitgen Inc. (CN) | 2025-11-26 | — | — | EP | disclosed |
| EP-4587438-A1 | BICYCLIC COMPOUNDS AS CDK INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-07-23 | — | — | EP | disclosed |
| CN-119894890-A | Bicyclic compounds as CDK inhibitors | 百济神州(苏州)生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-3956033-B1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240400556-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024216154-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-10-17 | — | — | WO | disclosed |
| US-12103902-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240293392-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-09-05 | — | — | US | disclosed |
| US-20170196867-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-9526727-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICAL, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2822930-B1 | INHIBITORS OF BETA-SECRETASE | BOEHRINGER INGELHEIM INT (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-20150150872-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-8981112-B2 | Inhibitors of β-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2822930-A1 | INHIBITORS OF BETA-SECRETASE | Boehringer Ingelheim International GmbH (DE) | 2015-01-14 | — | — | EP | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-20130289050-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2013134085-A1 | INHIBITORS OF BETA-SECRETASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |